The shares of a leading pharmaceutical company, specializing in manufacturing and trading pharmaceutical products hit a 20 percent upper circuit following a Bulk deal involving Samvitti Capital – Active Alpha Multicap.
Price action
With a market capitalization of Rs. 1,619.09 crores on Thursday, the shares of Windlas Biotech Limited hit a 20 percent upper circuit making a high of Rs. 811.20 per share compared to its previous closing price of Rs. 676.00 per share.
What Happened
Windlas Biotech Limited engaged in manufacturing and trading pharmaceutical products, recently experienced a bulk deal, in which Samvitti Capital – Active Alpha Multicap sold 1.15 lakh shares consisting of a 0.55 percent stake at Rs. 683.49 apiece on February 19, resulting in a total value of around Rs. 7.86 Crores.
About the company
Windlas Biotech Limited is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of generic medicines, including tablets, capsules, syrups, and topical products. The company offers services in both the over-the-counter and prescription drug sectors.
Key Profitability Metrics
The company has reported a 22 percent YoY increase in EBITDA to Rs. 68.6 crores for 9 months FY25 with a margin of 12.3 percent, PAT for 9 months FY25 stood at Rs. 44.7 crores, up 9 percent YoY, while Q3 FY25 PAT was Rs. 15.6 crores, reflecting a 3 percent YoY growth.
Future Growth Projections
The management is optimistic about the new injectable facility, expecting it to boost revenue and margins as production increases and they aim to maintain operating margins while managing the costs of the new facility during its ramp-up phase.
Financials
The company’s total revenue rose by 20.4 percent from Rs. 165.37 crore to Rs. 199.13 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 15.1 crore to Rs. 15.58 crore during the same period.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
